REGENXBIO Q3 net loss $58.4M; AbbVie collaboration for RGX-314 with $370M upfront

REGENXBIO Inc.

2021-Q3 EPS reported -$3.93 revenue$71,692,000

AbbVie collaboration: $370M upfront, up to $1.38B milestones, 50/50 U.S. profit share.
Q3 revenue $30.8M (prior year $98.9M included $80M milestone); net loss $58.4M vs prior year net income $8.8M.
Cash $533.5M; expects to fund operations into H2 2023, excluding AbbVie deal proceeds.
RGX-314 Phase II: stable visual acuity and reduced anti-VEGF burden in wet AMD; 33% of DR patients improved ≥2 steps.
IND for RGX-202 for Duchenne muscular dystrophy on track for end of 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.